Merilog is a rapid-acting human insulin analog designed to reduce spikes in blood sugar levels that typically occur during mealtime. This approval extends to a 3-milliliter single-patient-use ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

President and CEO Ned McCoy shared with Becker's some of the company's key objectives for the year, including the launch of some of the first medications from its Petersburg, Va.-based plant, the ...

Biocon Biologics unit and USA-based Civica Rx, a not-for-profit generic drug and pharmaceutical company, have announced a ...

South Africa's Competition Commission investigates Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market.

Biocon Biologics on Thursday said it has tied up with not-for-profit generic drug and pharmaceutical firm Civica, Inc to expand access and affordability of Insulin Aspart in the US.

Biocon Biologics partners with Civica Inc to increase affordability and access to Insulin Aspart in the US, targeting the ...

The 26-week, open-label clinical trial randomized 230 pediatric subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA) in combination with ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...

a rapid-acting insulin analog, at its manufacturing facility in Petersburg, Virginia. Civica will commercialize the medicine for patients in the United States, after completion of development work ...